Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cone-Rod Dystrophy: early-phase trial registry
5 of 5 indexed Cone-Rod Dystrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Cone-Rod Dystrophy: 5 US clinical trials tracked, 5 recruiting.
Cone-Rod Dystrophy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Ascidian Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition cone-rod-dystrophy
OPEN 5 | RECR 100% | LATE 0 | EARLY 3 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Cone-Rod Dystrophy lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cone-Rod Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cone-Rod Dystrophy is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cone-Rod Dystrophy research.
Ascidian Therapeutics accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Cone-Rod Dystrophy trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Cone-Rod Dystrophy splits between interventional and observational designs.
3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
University of Colorado, Denver
NCT01773278
Adaptive Optics Imaging of Outer Retinal Diseases
Food and Drug Administration (FDA)
NCT05355415
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
BlueRock Therapeutics
NCT06789445
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Ascidian Therapeutics
NCT06445322
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Ascidian Therapeutics
NCT06467344
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cone-Rod Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cone-Rod Dystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cone-Rod Dystrophy page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Cone-Rod Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ascidian Therapeutics sponsors the most Cone-Rod Dystrophy trials on record, review their full trial history before evaluating a specific study. See Ascidian Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cone-Rod Dystrophy condition card totals 5 registered trials; most-linked intervention Prescreening Assessments; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.